Latest Breaking News On - Short form base shelf prospectus - Page 4 : comparemela.com

TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES Akwaaba Mining Ltd. BULLETIN TYPE: Consolidation BULLETIN DATE: 17, 2023 TSX Venture Tier 2 Company Pursuant to a special resolution passed by shareholders March 31, 2023, the Company has consolidated its capital on a old for. - Veroeffentlicht am 18.10.2023

British columbiaUnited statesUnited kingdomExchange ratioCompany formPro group involvementMineral exploration developmentMarket regulator of the exchangeVenture exchange theCormark securities incVenture exchangeArm length party involvementInvestment industry regulatory organization of canadaShort form base shelf prospectusLithium one metals incCraig hallum capital group

NervGen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo,.

United statesUnited kingdomBritish columbiaNancy thompsonHuitt traceyJim balsillieJohn ruffoloVenture exchangeCompany board of directorsBritish columbia newsfile corpInvestigative journalism foundationShort form base shelf prospectusAi partnerships corpCouncil of canadian innovatorsRegulation services providerShopify inc

TSX Venture Exchange Stock Maintenance Bulletins

Consolidation BULLETIN DATE: 27, 2023. TSX Venture Tier 2 Company Pursuant to a Directors resolution dated 13, 2023, the Company has consolidated its capital on a Ten old for One new basis. The name of the Company has not been changed. Effective at. - Veroeffentlicht am 28.09.2023

British columbiaUnited statesParadigm capital incCharity flowAmerican eagle gold corpCharity ft sharePro group involvementInsider pro group participationLength party involvementMarket regulator of the exchangeVenture exchangeOrganto foods incPro groupBattery materials ltdVenture exchange theCompany rights offering on

NervGen Pharma Corp : NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

NervGen Pharma Corp : NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baden wübergBritish columbiaUnited kingdomUnited statesRehabilitation institute of chicagoNorthwestern universityShirley ryan abilitylabHuitt traceyNancy thompsonMike kellyMonicaa perezEdward hines jrNervgen pharma corpCorporate communicationsWings for life accelerated translational programResearch scientist

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the first subject has been dosed in.

British columbiaUnited statesUnited kingdomNorthwestern universityRehabilitation institute of chicagoEdward hines jrMike kellyHuitt traceyNancy thompsonMonicaa perezShirley ryan abilitylabCorporate communicationsNervgen pharma corpWings for life accelerated translational programResearch scientistBritish columbia newsfile corp